Monday, May 10, 2021 |

Maryland-based Novavax phase 3 clinical trial expands to include children 12 to 17

May 4, 2021

A Maryland-based COVID-19 vaccine producer is expanding its late-stage Phase 3 clinical trial study to include children ages 12 to 17. Novavax, headquartered in Gaithersburg, will assess the safety and effectiveness of its protein-based immunization on up to 3,000 adolescents across the United States, the company said Monday. Participants in the study will be monitored for two years after the last injection.

Article Source: Baltimore Sun

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.